Insights about U.S. Stocks that landed in the Green-Zone during Wednesday’s trade, are depicted underneath:
HCA Holdings Inc (NYSE:HCA)’s shares picked up 5.85%, and closed at $74.93, hitting new 52-week high of $77.08. The company holds the market capitalization of 31.51B. The stock return on equity value is - 24.10%, while return on assets value is - 6.20%, in response to its return on investment value of 18.60%. Its 20-day moving average gained 7.42%, and the stock moved below 50-day moving average of 5.04%. The mean recommendation of analysts for this stock is 1.80.(where 1=Buy, 5=Sale).
Dreamworks Animation Skg Inc (NASDAQ:DWA), raised 5.74%, and closed at $21.74.
Formerly on February 24, DreamWorks Animation SKG Inc. (DWA), stated proceeds for the quarter ended December 31, 2014 of $234.2 million, representing an raise of 14.7% from the same period in 2013. In addition, DWA stated an adjusted operating loss of $(37.6) million and adjusted net loss attributable to DWA of ($64.1) million or an adjusted loss of ($0.75) per share. Adjusted financial results exclude a $210.1 million pre-tax charge associated with Corporation’s restructuring plan declared on January 22, 2015. The Corporation’s results for the quarter ended December 31, 2014 comprise impairment charges of $57.1 million, or a loss of about $(0.63) per share, primarily related to the performance of The Penguins of Madagascar and Mr. Peabody and Sherman, in addition to certain other titles and investments.
Counting the influence of the restructuring plan, DWA stated an operating loss of ($247.7) million and stated net loss attributable to DWA of ($263.2) million, or ($3.08) per share for the quarter ended December 31, 2014. Of the restructuring-related charges totaling $210.1 million or a loss of ($2.33) per share, $54.6 million was related to employee termination costs and other contractual obligations and $155.5 million was primarily related to write-offs of capitalized production costs of unreleased projects, counting B.O.O. and Monkeys of Mumbai, in addition to other charges associated with changes in the film slate.
DreamWorks Animation creates high-quality entertainment, counting CG animated feature films, television specials and series and live entertainment properties, meant for audiences around the world. The Corporation has world-class creative talent, a strong and practiced administration team and advanced filmmaking technology and techniques.
Galena Biopharma Inc (NASDAQ:GALE), enhanced 5.41%, and closed at $1.95.
Galena Biopharma, Inc. (GALE), a biopharmaceutical corporation developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, recently declared that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the 27th Annual ROTH Conference. The presentation will take place on Monday, March 9, 2015 at 8:00 a.m. PT at the Ritz Carlton Hotel in Laguna Nigel, CA.
Galena Biopharma, Inc., a biopharmaceutical corporation, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care.
Sangamo Biosciences, Inc (NASDAQ:SGMO), rose 5.27%, and closed at $17.98.
Formerly on February 26, Sangamo Biosciences Inc. (SGMO), declared the presentation of new clinical data from its Phase 1/2 clinical trial (SB-728-1101). The study is designed to evaluate SB-728-T, a ZFP Therapeutic® generated by ZFN-mediated genome editing of T-cells to knockout the CCR5 gene, which encodes a critical co-receptor for HIV infection. SB-728-T is being developed as a potential ‘functional cure’ for HIV/AIDS.
The 1101 study was designed to evaluate the effect of increasing doses of Cytoxan® preconditioning as a method to maximize engraftment of ZFN- modified cells (SB-728-T) in which both copies of the CCR5 gene had been disrupted, making the cells fully resistant to HIV infection. Data from Cohorts 1-5 of the 1101 study (18 subjects) demonstrated a dose-related raise in both total CD4 T-cell and ZFN modified CD4 T-cell engraftment in response to Cytoxan preconditioning up to 1.0 g/m2. In addition, all subjects underwent a TI and were taken off ART at sixteen weeks post infusion. Four subjects from Cohort 1-5 remain on long-term TI and have remained off ART for at least 40 weeks.
Sangamo BioSciences, Inc. is focused on Engineering Genetic CuresTM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Corporation has clinical stage programs to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728-T), beta-thalassemia (SB-BCLmR-HSPC), and NGF-AAV for Alzheimer’s disease (CERE-110).
